Browse history interactively

Page 1

Page 1Revision 1

Page 2

Page 2Revision 2

← Previous editContent deleted Content addedVisualWikitext

Revision as of 09:01, 18 April 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (← Previous edit		Latest revision as of 10:52, 7 November 2024 edit undoHoffmacs (talk | contribs)347 editsm Added links to other Wiki pages
(30 intermediate revisions by 20 users not shown)
Line 1:		Line 1:
			{{Short description|Chemical compound}}
	{{Drugbox		{{Drugbox
			| Verifiedfields = changed
⚫	| verifiedrevid = 411550415
			| Watchedfields = changed
⚫	| IUPAC_name = N,N,2-Trimethyl-5-nitro-benzenesulfonamide
		⚫	| verifiedrevid = 424658335
	| image = BRL50481_structure.png
		⚫	| IUPAC_name = ''N'',''N'',2-Trimethyl-5-nitrobenzenesulfonamide
⚫	| CAS_number = 433695-36-4
			| image = BRL-50,481.svg
⚫	| ATC_prefix =
			| width = 150
⚫	| ATC_suffix =
⚫	| PubChem = 2921148
⚫	| DrugBank =
⚫	| C=9|H=12|N=2|O=4|S=1
	| molecular_weight = 244.267 g/mol
⚫	| smiles = Cc1ccc(N(=O)=O)cc1S(=O)(=O)N(C)C
⚫	| bioavailability =
⚫	| protein_bound =
⚫	| metabolism =
⚫	| elimination_half-life =
⚫	| excretion =
⚫	| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫	| pregnancy_US = <!-- A / B / C / D / X -->
⚫	| pregnancy_category=
⚫	| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
⚫	| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫	| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫	| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫	| legal_status =
⚫	| routes_of_administration =
⚫	}}
			<!--Clinical data-->
⚫	'''BRL-50481''' is a drug developed by ] which is the first compound that acts as a ] selective for the PDE<sub>7</sub> subtype.<ref>Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA. Discovery of BRL 50481 , a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. ''Molecular Pharmacology''. 2004 Dec;66(6):1679-89. PMID 15371556</ref> It has been shown to increase mineralisation activity in ]s, suggesting a potential role for ]s in the treatment of ].<ref>Pekkinen M, Ahlström ME, Riehle U, Huttunen MM, Lamberg-Allardt CJ. Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts. ''Bone''. 2008 Jul;43(1):84-91. PMID 18420479</ref>
			| tradename =
		⚫	| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
		⚫	| pregnancy_US = <!-- A / B / C / D / X -->
		⚫	| pregnancy_category =
		⚫	| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
		⚫	| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
		⚫	| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
		⚫	| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
		⚫	| legal_status =
		⚫	| routes_of_administration =
			<!--Pharmacokinetic data-->
		⚫	| bioavailability =
		⚫	| protein_bound =
		⚫	| metabolism =
		⚫	| elimination_half-life =
		⚫	| excretion =
			<!--Identifiers-->
			| IUPHAR_ligand = 5154
			| CAS_number_Ref = {{cascite|correct|??}}
		⚫	| CAS_number = 433695-36-4
			| UNII_Ref = {{fdacite|correct|FDA}}
			| UNII = 03G869PR3P
		⚫	| ATC_prefix = None
		⚫	| ATC_suffix =
		⚫	| PubChem = 2921148
			| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
		⚫	| DrugBank =
			| ChEBI = 93472
			| ChEMBL_Ref = {{ebicite|changed|EBI}}
			| ChEMBL = 484928
			| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
			| ChemSpiderID = 2194720
			<!--Chemical data-->
		⚫	| C=9 | H=12 | N=2 | O=4 | S=1
		⚫	| smiles = Cc1ccc(N(=O)=O)cc1S(=O)(=O)N(C)C
			| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
			| StdInChI = 1S/C9H12N2O4S/c1-7-4-5-8(11(12)13)6-9(7)16(14,15)10(2)3/h4-6H,1-3H3
			| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
			| StdInChIKey = IFIUFCJFLGCQPH-UHFFFAOYSA-N
		⚫	}}
		⚫	'''BRL-50481''' is a drug developed by ] which is the first compound that acts as a ] selective for the ] family.<ref>{{cite journal | vauthors = Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA | display-authors = 6 | title = Discovery of BRL 50481 , a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes | journal = Molecular Pharmacology | volume = 66 | issue = 6 | pages = 1679–89 | date = December 2004 | pmid = 15371556 | doi = 10.1124/mol.104.002246 | s2cid = 9491524 | url = http://molpharm.aspetjournals.org/content/molpharm/66/6/1679.full.pdf }}</ref> PDE7 activity is encoded by two genes, ] and ]. BRL-50481 actually shows about an 80-fold preference for the ] subtype, for which it was developed, over ].<ref>{{cite journal | vauthors = Alaamery MA, Wyman AR, Ivey FD, Allain C, Demirbas D, Wang L, Ceyhan O, Hoffman CS | display-authors = 6 | title = New classes of PDE7 inhibitors identified by a fission yeast-based HTS | journal = Journal of Biomolecular Screening | volume = 15 | issue = 4 | pages = 359–67 | date = April 2010 | pmid = 20228279 | pmc = 2854023 | doi = 10.1177/1087057110362100 }}</ref> BRL-50481 has been shown to increase mineralisation activity in ]s, suggesting a potential role for ]s in the treatment of ].<ref>{{cite journal | vauthors = Pekkinen M, Ahlström ME, Riehle U, Huttunen MM, Lamberg-Allardt CJ | title = Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts | journal = Bone | volume = 43 | issue = 1 | pages = 84–91 | date = July 2008 | pmid = 18420479 | doi = 10.1016/j.bone.2008.02.021 }}</ref>
	==References==		== References ==
			{{reflist}}
	<references/>
	{{Phosphodiesterase inhibitors}}		{{Phosphodiesterase inhibitors}}
	]		]
	]		]
	]		]
			]
			]